References
Chok AY, Goh BK, Koh YX, et al. Validation of the MSKCC gastrointestinal stromal tumor nomogram and comparison with other prognostication systems: single-institution experience with 289 patients. Ann Surg Oncol. 2015;22:3597–605.
Joensuu H, Vehtari A, Riihimäki J, et al. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol. 2012;13:265–74.
Winer JH, Raut CP. Management of recurrent gastrointestinal stromal tumors. J Surg Oncol. 2011;104:915–20.
Sutton TL, Walker BS, Billingsley KG, et al. ASO visual abstract: the disease-free interval is associated with oncologic outcomes in patients with recurrent gastrointestinal stromal tumor. Ann Surg Oncol. 2021. https://doi.org/10.1245/s10434-021-10107-w.
Zink S, Kayser G, Gabius HJ, Kayser K. Survival, disease-free interval, and associated tumor features in patients with colon/rectal carcinomas and their resected intra-pulmonary metastases. Eur J Cardiothorac Surg. 2001;19:908–13.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Sutton, T.L., Heinrich, M.C. & Mayo, S.C. ASO Author Reflections: The Disease-Free Interval is Associated with Oncologic Outcomes for Patients with Recurrent Gastrointestinal Stromal Tumor. Ann Surg Oncol 28, 7921–7922 (2021). https://doi.org/10.1245/s10434-021-10103-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-021-10103-0